CSL to defend patent claims
AUSTRALIAN vaccines and blood products developer CSL has said it will vigorously fight a patent infringement claim launched by US- based biotech Bioverativ in relation to CSL’s haemophilia B drug, Idelvion.
Bioverativ, which develops treatments for haemophilia and other rare blood disorders, has filed complaints in the US District Court for the District of Delaware and with the International Trade Commission.
Bioverativ claims that Idelvion infringes three Bioverativ patents. “CSL is highly confident of its intellectual property position for Idelvion, a product of over a decade of innovative research by CSL Behring … and will vigorously defend against the claim,” CSL said in a statement yesterday.